Enanta Pharmaceuticals Inc expected to post a loss of $1.14 a share - Earnings Preview

Enanta Pharmaceuticals

09/05/2025 12:55

Enanta Pharmaceuticals Inc ENTA.OQ ENTA.O is expected to show a fall in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Watertown Massachusetts-based  company is expected to report a 6.5% decrease in revenue to $15.952 million from $17.05 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Enanta Pharmaceuticals Inc is for a loss of $1.14 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $19.00​, above​ its last closing price of $5.32. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.36
-1.35
-1.05
Beat
22.4
Sep. 30 2024
-1.10
-1.16
-1.36
Missed
-17.2
Jun. 30 2024
-1.40
-1.45
-1.07
Beat
26.2​
Mar. 31 2024
-1.39
-1.30
-1.47
Missed
-13.2
​​Dec. 31 2023
-1.19
-1.19
-1.58
Missed
-32.3
Sep. 30 2023
-2.17
-2.15
-1.33
Beat
38​
Jun. 30 2023
-2.37
-2.34
-1.86
Beat
20.4
Mar. 31 2023
-1.94
-1.98
-1.79
Beat
9.6

This summary was machine generated May 9 at 11:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)